European Mobtechs Dominate the Supply Market for Mobility-as-a-Service
7.3.2019 20:12:00 EET | Business Wire | Press release
A new study by PTOLEMUS Consulting Group finds that 12 of the top 17 B2B mobility platform providers in the world have their headquarters in Europe. These software suppliers have diverse backgrounds in road operation or technology but are all helped by a favourable environment and numerous city initiatives in Europe.
Frederic Bruneteau, PTOLEMUS’ Managing Director, stated: “While India just launched a vertically integrated national MaaS scheme, mobtechs are proposing a different model that relies on open software platforms for everybody to use. They are giving mobility operators an alternative to the inevitable dogfights between those who will eat (integrate) and those who will be eaten (integrated). This report sheds light on the specialist players that compete alongside government initiatives and giants such as Google and Uber”.
The Mobility Platform Suppliers handbook is the first to identify and appraise MaaS software suppliers and to clarify a very complex market. It will help cities, Public Transport Operators and mobility service providers choose the optimal model and deliver seamless mobility experiences.
The report maps the MaaS value chain and stakeholders. It also establishes the 6 levels of integration needed to deliver a complete MaaS solution. It includes an assessment of 17 key mobility platform suppliers, detailing their key clients, services, investors and case studies.
The handbook unpacks the MaaS ecosystem, stakeholders and architecture, covering:
- The necessary building blocks for a complete mobility platform
- The levels of MaaS integration
- The main players in each part of the MaaS value chain
- The top mobility platform providers
The study features:
- 150 pages of analysis of the complex ecosystem powering mobility-as-a-service,
- 17 MaaS platform suppliers assessed
- High level architecture of shared mobility platforms
- An independent ranking of the top technology providers in the MaaS market.
Download the abstract of the study here.
To discuss these questions directly with the authors, contact us at mobtech@ptolemus.com.
Suppliers analysed:
9 Transport Platform Providers:
- Bestmile
- INVERS
- Ecomobix
- Launch Mobility
- Omoove (Octo Telematics)
- Padam
- Ridecell
- Shotl
- Vulog
8 Mobility Platform Providers:
- A-to-Be (Brisa)
- Cubic
- Fluidtime (Kapsch)
- Moovel / Reach Now (BMW and Daimler)
- Moovit
- Optimile
- Siemens
- SkedGo
About PTOLEMUS Consulting Group
PTOLEMUS is the first strategy consulting & research firm entirely focused on connected & autonomous mobility. It assists leading public organisations, technology players, automotive OEMs, insurers and mobility service providers in defining & deploying their mobility strategies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005576/en/
Contact information
Annie Reddaway, +447912571379, areddaway@ptolemus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom